2015 ACC Medical Meeting Reporter: Best Practices in Lipid Management for Patients with Dyslipidemia
This Medical Meeting Reporter will focus on pivotal sessions and key clinical data related to new treatment and standards of care of patients with dyslipidemia presented at the 64th Annual American College of Cardiology (ACC) Scientific Sessions & Expo.
An expert panel will provide insight on current recommendations and review available and emerging therapeutics, including statin therapy and PCSK9 inhibitors. This CME activity will bring cardiologists and other physicians up-to-date on clinical trial data and the management of patients with dyslipidemia.
Cardiologists, internists, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with dyslipidemia.
Upon completion of this activity, participants will be able to:
- Discuss treatment guidelines and recommendations for appropriate patient assessment, treatment selection, and risk stratification strategies within dyslipidemia.
- Analyze available and emerging dyslipidemia therapeutics, including statin therapy and PCSK9 inhibitors.
- Formulate personalized treatment plans to accurately assess patient-specific characteristics, optimizing therapeutic selection to improve outcomes in dyslipidemia.
Christopher P. Cannon, MD
Robert P. Giugliano, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Relationship Identified With:
Christopher P. Cannon, MD
Consultant/Advisor: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; CSL Behring; Essentialis; GlaxoSmithKline plc.; Kowa Pharmaceuticals America, Inc.; LipoMedix; Merck & Co., Inc.; Pfizer Inc.; Sanofi US and Regeneron Pharmaceuticals Alliance; Takeda Pharmaceutical Company Limited
Grant/Research Support: Accumetrics; Arisaph Pharmaceuticals, Inc.; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline plc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Takeda Pharmaceutical Company Limited
Robert P. Giugliano, MD
Consultant/Advisor: Amgen Inc.; Beckman-Coulter, Inc.; Daiichi-Sankyo Company, Limited; Janssen Pharmaceuticals, Inc.; Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Portola Pharmaceuticals, Inc.; Pfizer Inc.; Sanofi US and Regeneron Pharmaceuticals Alliance
Grant/Research Support: Amgen Inc.; Daiichi-Sankyo Company, Limited; Merck & Co., Inc.
Speakers' Bureau: Amgen Inc.; Bristol-Myers Squibb Company; Daiichi-Sankyo Company, Limited; Merck & Co., Inc.; Sanofi US and Regeneron Pharmaceuticals Alliance
Deepak L. Bhatt, MD
Grant/Research Support: Amarin Corp.; AstraZeneca; Bristol-Myers Squibb Company; Eisai Inc.; Ethicon US, LLC.; F. Hoffmann-La Roche Ltd; Forest Laboratories, Inc.; Ischemix; Medtronic plc.; Pfizer Inc.; Sanofi US and Regeneron Pharmaceuticals Alliance; St. Jude Medical, Inc.; The Medicines Company
Planners, Managers, Reviewers: Sandy Breslow; Brynne Hunter; Jacquelyn Valerio; Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin; Jaimie Kelly; and Bernard Abrams, MD hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME
Course Open Date: June 15, 2015 | Course Expiration Date: June 14, 2016
Credit Designation Statement
The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Amgen, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, AcademicCME and Amgen, Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician